Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Intern Med ; 285(1): 59-74, 2019 01.
Article in English | MEDLINE | ID: mdl-30102798

ABSTRACT

BACKGROUND: Plaque angiogenesis is associated with atherosclerotic lesion growth, plaque instability and negative clinical outcome. Plaque angiogenesis is a natural occurring process to fulfil the increasing demand of oxygen and nourishment of the vessel wall. However, inadequate formed, immature plaque neovessels are leaky and cause intraplaque haemorrhage. OBJECTIVE: Blockade of VEGFR2 normalizes the unbridled process of plaque neovessel formation and induces maturation of nascent vessels resulting in prevention of intraplaque haemorrhage and influx of inflammatory cells into the plaque and subsequently increases plaque stability. METHODS AND RESULTS: In human carotid and vein graft atherosclerotic lesions, leaky plaque neovessels and intraplaque haemorrhage co-localize with VEGF/VEGFR2 and angiopoietins. Using hypercholesterolaemic ApoE3*Leiden mice that received a donor caval vein interposition in the carotid artery, we demonstrate that atherosclerotic vein graft lesions at t28 are associated with hypoxia, Hif1α and Sdf1 up-regulation. Local VEGF administration results in increased plaque angiogenesis. VEGFR2 blockade in this model results in a significant 44% decrease in intraplaque haemorrhage and 80% less extravasated erythrocytes compared to controls. VEGFR2 blockade in vivo results in a 32% of reduction in vein graft size and more stable lesions with significantly reduced macrophage content (30%), and increased collagen (54%) and smooth muscle cell content (123%). Significant decreased VEGF, angiopoietin-2 and increased Connexin 40 expression levels demonstrate increased plaque neovessel maturation in the vein grafts. VEGFR2 blockade in an aortic ring assay showed increased pericyte coverage of the capillary sprouts. CONCLUSION: Inhibition of intraplaque haemorrhage by controlling neovessels maturation holds promise to improve plaque stability.


Subject(s)
Hemorrhage/prevention & control , Neovascularization, Pathologic/prevention & control , Plaque, Atherosclerotic/drug therapy , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Angiopoietin-2/blood , Animals , Biomarkers/blood , Connexins/blood , Disease Models, Animal , Humans , Mice , Vascular Endothelial Growth Factor A/blood , Vascular Endothelial Growth Factor A/pharmacology , Gap Junction alpha-5 Protein
2.
Minerva Cardioangiol ; 57(5): 621-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19838152

ABSTRACT

Drug eluting stents (DES) have significantly reduced restenosis when compared to BMS and are considered the standard of care in the treatment of symptomatic coronary artery disease. However, late stent thrombosis has emerged as a major concern with the use of first generation DES. Pathologic studies of patients dying from late DES thrombosis (first generation sirolimus-eluting stents and paclitaxel-eluting stents) showed that DES are associated with delayed healing characterized by poor endothelialization of stent struts and persistence of fibrin as compared to BMS. Additional risk factors for LST include long lesions, left main coronary artery, bifurcation stenting, ruptured plaques, and hypersensitivity reactions. Currently, the next generation DES are being developed to optimize the three major components of DES: the stent platform, the polymer coating and the drug. New technologies include biodegradable polymers and stents, polymer free drug delivery and prohealing approaches. Further preclinical testing and evaluation through large clinical trials are needed to determine the safety and efficacy of future DES in clinical practice.


Subject(s)
Drug-Eluting Stents/adverse effects , Vascular Diseases/etiology , Animals , Blood Vessels/pathology , Humans
4.
Curr Opin Cardiol ; 16(5): 285-92, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11584167

ABSTRACT

While the concept of plaque 'vulnerability' implies a propensity towards thrombosis, the term vulnerable was originally intended to provide a morphologic description consistent with plaques that are prone to rupture. It is now known that the etiology of coronary thrombi is diverse and can arise from entities of plaque erosion or calcified nodules. These findings have prompted the search for more definitive terminology to describe precursor lesions associated with rupture, now referred to as thin-cap fibroatheromas. This review focuses on the thin-cap fibroatheroma, as a specific cause of acute coronary syndromes. To put these issues into current perspective, we need to revisit some of the older literature describing plaque morphology in stable and unstable angina, acute myocardial infarction, and sudden coronary death. The morphology, frequency, and precise location of these thin-cap fibroatheromas are further discussed in detail. Potential mechanisms of fibrous cap thinning are also addressed, in particular emerging data, which suggests the role of cell death "apoptosis" in cap atrophy.


Subject(s)
Coronary Artery Disease/physiopathology , Acute Disease , Angina Pectoris/epidemiology , Angina Pectoris/etiology , Angina Pectoris/physiopathology , Coronary Artery Disease/epidemiology , Coronary Thrombosis/complications , Coronary Thrombosis/epidemiology , Coronary Thrombosis/physiopathology , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/etiology , Humans , Incidence , Rupture, Spontaneous/physiopathology
5.
Mol Ther ; 2(5): 496-504, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11082323

ABSTRACT

The utility of adenoviral vectors is limited by immune responses to adenoviral antigens. We sought to develop immune-competent mice in which the immune response to adenoviral antigens was selectively absent. To do so, we generated mice that were transgenic for a replication-defective vector. Adenoviral antigens might be seen as self-antigens by these mice, and the mice could exhibit immunologic tolerance after postnatal exposure to adenoviral vectors. In addition, characterization of these mice could reveal potential consequences of germline transmission of an adenoviral vector, as might occur in a gene therapy trial. Injection of a "null" (not containing a transgene) E1, E3-deleted vector genome into mouse zygotes yielded five founders that were capable of transmitting the vector genome. Among offspring of these mice, transgenic pups were significantly underrepresented: 108 of 255 pups (42%) were transgenic (P<0.02 versus expected frequency of 50%). Postnatal transgenic mice, however, had no apparent abnormalities. Persistence of an adenoviral vector after intravenous injection was equivalent in livers of transgenic mice and their nontransgenic littermates. Transgenic and nontransgenic mice also had equivalent humoral and cellular immune responses to adenoviral vector injection. Mice that are transgenic for an E1, E3-deleted adenoviral genome can be easily generated; however, they are not tolerant of adenovirus. Moreover, germline transmission of an adenoviral vector genome does not prevent generation of a robust immune response after exposure to adenoviral antigens.


Subject(s)
Adenoviridae/genetics , Adenoviridae/immunology , Defective Viruses/genetics , Genetic Vectors/immunology , Lymphocyte Activation , Adenoviridae/metabolism , Animals , Antibodies, Viral/biosynthesis , Antigens, Viral/immunology , Cells, Cultured , DNA, Viral/analysis , Defective Viruses/immunology , Defective Viruses/metabolism , Immune Tolerance , Mice , Mice, Transgenic , Spleen/cytology , Spleen/immunology , Transcriptional Activation , Transgenes , alpha 1-Antitrypsin/genetics , alpha 1-Antitrypsin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...